Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It can be used to treat these two distinct types of cancer because they are caused by related proteins — tyrosine kinases. However, this lack of specificity for a single protein means that imatinib can also inhibit tyrosine kinases that mediate normal bodily functions and it has been reported that in some patients this causes a toxic effect on the heart. To address some of these problems, Ariel Fernández and colleagues at Rice University, Houston, have engineered a modified form of imatinib (known as WBZ_4) that inhibited the tyrosine kinase behind GISTs (c-KIT) as effectively as imatinib did, and that neither inhibited the tyrosine kinase behind CML (BCR-Abl) nor had toxic effects on the heart when it was administered to mice. Importantly, WBZ_4 was as effective as imatinib at reducing tumor volume and weight in a mouse model of GISTs. As noted by George Demetri from the Dana-Farber Cancer Institute, Boston, in the accompanying commentary, this study gives hope that in the future it might be possible to construct “ever-better agents that can be combined safely and effectively to manage, and eventually cure, many forms of human cancer”.
TITLE: An anticancer C-Kit kinase inhibitor is reengineered to it more active and less cardiotoxic
AUTHOR CONTACT:
Ariel Fernández
Rice University, Houston, Texas, USA.
Phone: (713) 348-3681; Fax: (713) 348-3699; E-mail: arifer@rice.edu .
MEDIA CONTACT:
Jade C. Boyd
Associate Director of News & Media Relations
Rice University, Houston, Texas, USA.
Phone: (713) 348-6778; E-mail: jadeboyd@rice.edu .
View the PDF of this article at: https://www.the-jci.org/article.php?id=32373
ACCOMPANYING COMMENTARY
TITLE: Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
AUTHOR CONTACT:
George D. Demetri
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Phone: (617) 632-3985; Fax: (617) 632-3408; E-mail: gdemetri@partners.org .
View the PDF of this article at: https://www.the-jci.org/article.php?id=34252
Journal of Clinical Investigation